Recent Finacing
Recent Raise
Oric Pharmaceuticals discovers and develops small-molecule therapies for treatment-resistant cancers, advancing GR inhibitor ORIC-101 in Phase 1 and modeling tumor resistance to identify targets and combination regimens.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at ORIC Pharmaceuticals.
